![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
HEPATITIS C VIRUS REINFECTION AND INJECTING RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR TREATMENT IN PARTICIPANTS ON OPIATE AGONIST THERAPY: C-EDGE CO-STAR PART B
|
|
|
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Jason Grebely1, Alain H. Litwin2, Olav Dalgard3, Edward J. Gane4, Oren Shibolet5, Brian Conway6, Ronald Nahass7, Frederick Altice8, Anne Luetkemeyer9, Cheng-Yuan Peng10, David Iser11, Isaias N. Gendrano12, Michelle M. Kelly12, Hsueh-Cheng Huang12, Peggy Hwang12, Eliav Barr12, Michael Robertson12, Heather Platt12,Gregory Dore1
![1116181](../images%20/111618/111618-10/1116181.gif)
![1116182](../images%20/111618/111618-10/1116182.gif)
![1116183](../images%20/111618/111618-10/1116183.gif)
![1116184](../images%20/111618/111618-10/1116184.gif)
![1116185](../images%20/111618/111618-10/1116185.gif)
![1116186](../images%20/111618/111618-10/1116186.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|